Recilisib

Drug Profile

Recilisib

Alternative Names: Ex-RAD; ON 01210.Na; ON-01210; ON-01210-Na; Recilisib sodium

Latest Information Update: 21 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Onconova Therapeutics
  • Class Radioprotectives; Small molecules; Sulfonamides
  • Mechanism of Action Apoptosis inhibitors; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Acute radiation syndrome

Most Recent Events

  • 21 May 2018 Recilisib is still in phase I trials for Acute Radiation Syndrome in USA (PO) (SC) (Onconova Therapeutics pipeline, May-2018)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Acute-radiation-syndrome in USA (PO, Liquid)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Acute-radiation-syndrome in USA (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top